SCHEMBL18077702

SCHEMBL18077702

Cn1cc(-c2cn(-c3ccc(OCF)cc3)c(=O)cc2OCCN2CCOCC2=O)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.44
PRKAB2 O43741 3/20 0.37
PRKAG1 P54619 3/20 0.37
PRKAA2 P54646 3/20 0.37
PRKAA1 Q13131 3/20 0.37
PRKAG3 Q9UGI9 3/20 0.37
PRKAG2 Q9UGJ0 3/20 0.37
PRKAB1 Q9Y478 3/20 0.37
MCHR1 Q99705 2/20 0.35
MAPK14 Q16539 4/20 0.35
MAPK10 P53779 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
GRM4 Q14833 1/20 0.34
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
MET P08581 1/20 0.33
HDAC1 Q13547 1/20 0.33
MAPK13 O15264 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474541 0.90 PDK2 (0.46) PDK2MCHR1PDE3BPDE3A
SCHEMBL18077687 0.88 MCHR1 (0.47) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL18077752 0.87 PDK2 (0.45) PDK2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL18812016 0.87 PDK2 (0.51) PDK2MAPK14CLK2CLK3GSK3B
SCHEMBL18812174 0.83 MAPK14 (0.53) MCHR1MAPK14HRH3CLK2CLK3
SCHEMBL18077663 0.83 MAPK14 (0.45) MCHR1MAPK14HRH3CLK2CLK3
SCHEMBL18077686 0.82 MET (0.39) MCHR1MAPK14HRH3GRM4CLK2
SCHEMBL18811810 0.81 AAK1 (0.43) HRH3
SCHEMBL18077662 0.80 MAPK14 (0.43) MCHR1MAPK14HRH3CLK2CLK3
SCHEMBL18077754 0.80 BRD4 (0.45) PDK2MCHR1MAPK14MAPK10MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PDK2 1258/4885PRKAB2 2755/4885PRKAG1 3031/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PDK2 1258/4885PRKAB2 2755/4885PRKAG1 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.